Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Gynecologic 3Thoracic 2Breast 2

Conditions

Prostatic Neoplasms 4Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Magnetic Resonance Spectroscopy 98Specimen Handling 79pembrolizumab 75enzalutamide 63Nivolumab 59Gemcitabine 54Docetaxel 50apalutamide 42Radiosurgery 41Abiraterone Acetate 40Androgen Antagonists 39Prednisone 38Biopsy 37darolutamide 35Cisplatin 35cabozantinib 31Radiotherapy 31Carboplatin 28Pluvicto 27abiraterone 26enfortumab vedotin 24Ipilimumab 24Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 18X-Rays 18Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
AZD5305 × Genitourinary × 90 days × Clear all
NCT05367440 2026-06-01

PETRANHA

AstraZeneca

Phase 1/2 Active not recruiting
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT06120491 2026-05-27

EvoPAR-PR01

AstraZeneca

Phase 3 Active not recruiting
1,889 enrolled
Genitourinary

Prostatic Neoplasms

NCT06952803 2026-05-19

EvoPAR-PR02

AstraZeneca

Phase 3 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

NCT07336446 2026-05-01

ANDROMEDA

AstraZeneca

Phase 1/2 Recruiting
300 enrolled
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡